According to Divine Skin, the new hair-growth molecule has been designed to stimulate hair follicles at the vertex of the scalp.
With respect to both efficacy and tolerability, is claimed to surpass the company's current hair-growth chemical on the market, Minoxidil, which is used in Divine Skin's own product Spectral DNC and has been on the market for around 30 years.
The company also claims that Nanoxidil has unique advantages over Minoxidil, particularly with respect to penetration and persistence, due to the fact that it has a lower molecular weight in comparison to Minoxidil, which leads to greater absorbtion and efficacy.
Spectral.DNC-N, part of the DS Laboratories brand, should be the first treatment to employ Nanoxidil, and the company says it could eventually succeed Minoxidil as the new standard for topical treatment.
Still under study
Divine Skin states that the compound’s precise mechanism is still under study, but that it expects the compound to enhance desirable properties whilst reducing side effects, in comparison to Minoxidil.
Studies carried out on Minoxidil have shown it to open ion channels, induce resting follicles in to growth phase, increase follicle size, relax vascular smooth muscle, and stimulate vascular endothelial growth factor.
“We expect Nanoxidil to become a powerful force in the fight against thinning and shedding hair, working faster and better with enhanced tolerability," predicted Daniel Khesin, CEO of Divine Skin.
"It may allow more patients to maintain their hair, and it may work for patients who have not responded to standard minoxidil therapy”.
Quick to market
The CEO stated further that the new Nanoxidil-containing products could be brought to market as Nanoxidil does not require health-agency approval in most countries.
He also anticipates that Divine Skin will see ‘significant’ revenue growth from Nanoxidil, which was five years in development.
Overall, Khesin commented on the debut, stating, "This is a significant step forward in topical therapy, and we are very excited”.